MedVellum
MedVellum
Back to Library

Hepatic Encephalopathy

On This Page

Overview

Hepatic Encephalopathy

Quick Reference

Critical Alerts

  • Must identify and treat precipitants: Infection (SBP), GI bleed, constipation, medications
  • Ammonia level doesn't correlate with severity: Clinical assessment is paramount
  • Risk of cerebral edema in acute liver failure: Different from chronic HE
  • Differentiate from other causes of AMS: Infection, intoxication, stroke, hypoglycemia
  • Lactulose is first-line treatment: Goal is 2-3 soft stools daily
  • Check for infection: SBP is common precipitant in cirrhosis

Key Diagnostics

TestFindingSignificance
AmmoniaMay be elevatedDoesn't correlate with severity; not required
CBCLeukocytosisMay indicate infection
CMPElectrolytes, glucose, renal functionPrecipitant identification
LFTsElevated bilirubin, low albuminAssess liver function
INRProlongedSynthetic dysfunction
Blood culturesPositiveSepsis
UrinalysisUTICommon precipitant
Diagnostic paracentesisPMN >50/μLSBP diagnosis

Emergency Treatments

ConditionTreatmentDose
First-lineLactulose30-45 mL PO q1-2h until bowel movement, then TID-QID
Rectal if unable to take POLactulose enema300 mL in 700 mL water
AdjunctiveRifaximin550 mg PO BID
InfectionAntibioticsCeftriaxone 2g IV for presumed SBP
GI bleedingPPI, octreotideStandard variceal bleed management
HypoglycemiaD5050 mL IV

Definition

Overview

Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric abnormalities occurring in patients with liver dysfunction, resulting from the accumulation of neurotoxins (primarily ammonia) that bypass hepatic metabolism. It ranges from subtle cognitive changes to deep coma and is usually precipitated by identifiable factors in patients with chronic liver disease.

Classification

By Type:

TypeSetting
Type AAcute liver failure (different physiology)
Type BPortosystemic bypass without intrinsic liver disease
Type CCirrhosis (most common)

By Severity (West Haven Criteria):

GradeDescriptionFindings
Covert (MHE + Grade I)Minimal or subclinicalPsychometric testing abnormal; mild confusion
Grade IMildShortened attention span, altered sleep, euphoria/anxiety
Grade IIModerateLethargy, disorientation to time, personality change, asterixis
Grade IIISevereSomnolence but arousable, gross disorientation, bizarre behavior
Grade IVComaUnresponsive to stimuli

By Course:

  • Episodic: Single episode with precipitant
  • Recurrent: Multiple episodes within 6 months
  • Persistent: Persistent cognitive impairment despite treatment

Epidemiology

  • Prevalence in cirrhosis: 30-45% will have overt HE at some point
  • Minimal HE: Present in 20-80% of cirrhotics (often undiagnosed)
  • Hospital readmissions: HE is leading cause of readmission in cirrhosis
  • Mortality: 30-50% 1-year mortality after first episode of overt HE

Etiology

Precipitating Factors (Most Important to Identify):

PrecipitantFrequencyMechanism
Infection (including SBP)25-30%Increased nitrogen load, inflammation
GI bleeding20-25%Protein load from blood in gut
Constipation15-20%Increased ammonia production and absorption
Dehydration/Electrolyte disturbance15%Hypokalemia, hyponatremia
Medications (sedatives, opioids)10-15%Direct CNS effect
Dietary protein excess5%Increased nitrogen load (less common)
Renal failureVariableDecreased ammonia clearance
TIPS placementVariableIncreased portosystemic shunting
Non-compliance with lactuloseCommonClear history of stopping medications
Unknown/No identifiable precipitant20-30%

Pathophysiology

Ammonia Hypothesis

  1. Ammonia production: Gut bacteria break down nitrogenous compounds
  2. Normally cleared by liver: Via urea cycle
  3. In liver failure/shunting: Ammonia bypasses liver, enters systemic circulation
  4. Crosses blood-brain barrier: Enters astrocytes
  5. Astrocyte swelling: Glutamine accumulation causes osmotic swelling
  6. Neurological dysfunction: Impaired neurotransmission, inflammation

Other Contributing Factors

  • Inflammation: Systemic inflammation from gut translocation amplifies ammonia's effects
  • Manganese: Accumulates in basal ganglia
  • GABA/Benzodiazepine-like substances: Enhanced GABAergic tone
  • Altered amino acids: Increased aromatic, decreased branched-chain
  • Oxidative stress: From multiple mechanisms

Differences: Acute Liver Failure vs Cirrhosis

FeatureAcute Liver Failure (Type A)Cirrhosis (Type C)
Cerebral edemaCommon, life-threateningRare
ICP elevationYesNo
Ammonia levelBetter correlate with severityPoor correlation
Treatment focusPrevent herniation, transplantTreat precipitants, lactulose

Clinical Presentation

Symptoms

Covert/Minimal HE:

Overt HE:

StageSymptoms
Grade IShortened attention, mood changes, sleep disturbance
Grade IIObvious personality change, inappropriate behavior, lethargy
Grade IIIMarked confusion, somnolence but arousable
Grade IVComa, unresponsive

History

Key Questions:

Physical Examination

General:

Neurological:

FindingDescription
Asterixis"Liver flap" - involuntary tremor with dorsiflexion of wrists
HyperreflexiaEarly stages
HyporeflexiaLate stages
RigidityExtrapyramidal signs
Fetor hepaticusMusty, sweet breath odor
Constructional apraxiaUnable to draw star, copy figures

Signs of Precipitating Factors:


Sleep disturbance (sleep-wake reversal)
Common presentation.
Impaired concentration
Common presentation.
Difficulty with complex tasks
Common presentation.
Often only detected on psychometric testing
Common presentation.
Red Flags

Life-Threatening Conditions

FindingConcernAction
Acute liver failure + HECerebral edema, herniationICU, ICP monitoring, transplant eval
GCS ≤8 or rapidly decliningAirway at riskIntubation, ICU
Fever + abdominal pain + ascitesSBPDiagnostic paracentesis, antibiotics
Hematemesis/melenaVariceal bleedingGI consultation, hemodynamic support
HypoglycemiaCommon in liver failureD50 administration
Refractory to treatmentAlternative diagnosis or severe diseaseReassess, consider intubation

Alternative Diagnoses to Consider

  • Alcohol intoxication or withdrawal
  • Hypoglycemia
  • Infection/Sepsis (causing delirium)
  • Stroke
  • Subdural hematoma (especially if falls or anticoagulation)
  • Medication overdose
  • Wernicke's encephalopathy
  • Uremia

Differential Diagnosis

AMS in Patients with Cirrhosis

DiagnosisDistinguishing FeaturesEvaluation
Hepatic encephalopathyLiver stigmata, asterixis, precipitant identifiedClinical diagnosis
Alcohol withdrawalTremor, autonomic instability, timeline from last drinkCIWA score
HypoglycemiaSymptoms improve with glucoseFingerstick glucose
Infection/SepsisFever, elevated WBC, sourceCultures, imaging
Subdural hematomaTrauma history, focal signs, coagulopathicCT head
StrokeFocal deficits, acute onsetCT/MRI
Drug overdoseKnown ingestion, toxidromeTox screen
Wernicke'sAtaxia, ophthalmoplegia, alcoholismClinical; give thiamine
Uremic encephalopathyElevated creatinine, ESRDBMP
PostictalWitnessed seizureHistory, EEG if unclear

Diagnostic Approach

Clinical Diagnosis

HE is a clinical diagnosis based on:

  1. Known liver disease or portal-systemic shunting
  2. Altered mental status (ranging from subtle to coma)
  3. Exclusion of other causes of AMS
  4. Identification of precipitant (if possible)

Laboratory Studies

TestRationaleNotes
AmmoniaMay support diagnosisDoes NOT correlate with severity; trend is more useful than single level
CBCInfection, bleedingLeukocytosis
CMPGlucose, electrolytes, renalHyponatremia, hypoglycemia, AKI
LFTsLiver synthetic functionElevated bilirubin
PT/INRCoagulopathyProlonged
Blood culturesSepsisIf fever or infection suspected
UrinalysisUTICommon precipitant
LactateSepsisHypoperfusion

Ammonia Interpretation:

  • Elevated ammonia supports but does not confirm diagnosis
  • Normal ammonia does not exclude HE
  • Single values less useful than trends
  • Do not use to titrate therapy

Diagnostic Paracentesis

Indications in HE:

  • Any patient with ascites and AMS (to rule out SBP)
  • Fever, abdominal pain, or tenderness

SBP Criteria:

  • PMN count ≥250 cells/μL = SBP (treat empirically)
  • Culture positive (may be delayed)

Imaging

CT Head:

  • Not routinely needed for classic HE presentation
  • Indicated if: Focal signs, head trauma, anticoagulated, atypical presentation
  • Rule out stroke, SDH, other structural causes

Psychometric Testing (For Minimal HE)

  • Number connection test
  • Digit symbol test
  • Critical flicker frequency
  • Not practical in acute setting

Treatment

Principles of Management

  1. Identify and treat precipitant (most important)
  2. Reduce ammonia levels via gut (lactulose)
  3. Supportive care (hydration, nutrition, airway)
  4. Consider rifaximin (adjunctive, reduces recurrence)
  5. Avoid sedatives (can worsen HE)
  6. Consider transplant evaluation for recurrent HE

Treat Precipitants

PrecipitantTreatment
Infection/SBPCeftriaxone 2g IV; adjust for culture
GI bleedingPPI, octreotide, urgent endoscopy
ConstipationLactulose, enemas
DehydrationIV fluids (avoid NS if possible - hyperchloremic acidosis)
Electrolyte disturbancesCorrection (K+, Na+)
MedicationsHold sedatives, opioids, diuretics
Renal failureFluids, hold nephrotoxins, consider RRT

Lactulose

First-Line Treatment:

RouteDoseGoal
Oral30-45 mL q1-2h until bowel movement, then TID-QID2-3 soft stools/day
Rectal (if unable to take PO)300 mL lactulose in 700 mL water as enemaRetain 30-60 min, repeat

Mechanism:

  • Decreases colonic pH → traps ammonia as ammonium (NH4+)
  • Cathartic effect removes nitrogenous material
  • Alters gut flora

Monitoring:

  • Too few stools → inadequate treatment
  • Excessive diarrhea → dehydration, hyponatremia, worsen HE

Rifaximin

Adjunctive Therapy:

DoseIndication
550mg PO BIDPrevention of recurrent HE; adjunct in acute

Mechanism:

  • Non-absorbable antibiotic
  • Reduces ammonia-producing gut bacteria

Evidence:

  • Reduces recurrence by 50% when added to lactulose
  • Expensive but effective

L-Ornithine L-Aspartate (LOLA)

  • Increases ammonia metabolism
  • Used in some countries
  • Evidence is mixed

Airway Protection

  • Intubate for GCS ≤8 or inability to protect airway
  • Consider for Grade III-IV HE
  • Avoid sedation if possible; use short-acting agents

Nutrition

  • Do NOT restrict protein (causes muscle wasting, may worsen HE)
  • Target 1.2-1.5 g/kg/day protein
  • Consider branched-chain amino acids in intolerant patients
  • Frequent small meals

Avoid Deleterious Medications

  • Benzodiazepines
  • Opioids
  • Proton pump inhibitors (may increase SBP risk)
  • Excessive diuretics (cause dehydration, hypokalemia)

Disposition

Admission Criteria

  • Grade II or higher HE (overt HE)
  • Any HE with identified precipitant requiring treatment (GI bleed, SBP)
  • Unable to take oral medications
  • Inadequate home support
  • Failure of outpatient management

ICU Criteria

  • Grade III-IV HE with airway concerns
  • Acute liver failure with HE
  • Concurrent GI bleeding or septic shock
  • Need for intubation

Discharge Criteria

  • Mental status returned to baseline
  • Precipitant treated
  • Tolerating PO lactulose
  • Adequate home support
  • Follow-up arranged with hepatology

Follow-Up

SituationFollow-Up
First episodeHepatology within 1-2 weeks
Recurrent HEHepatology urgent; transplant evaluation
On lactulose/rifaximinHepatology regular follow-up
RefractoryConsider embolization of shunts, transplant

Patient Education

Condition Explanation

  • "Your liver is not able to remove toxins from your blood effectively, and these toxins are affecting your brain."
  • "This is treatable, but we need to find out what triggered this episode."
  • "Lactulose works by helping your body get rid of these toxins through bowel movements."

Medication Instructions

Lactulose:

  • Take as prescribed; do not stop without physician guidance
  • Goal is 2-3 soft bowel movements per day
  • Too few = underdose → confusion may return
  • Too many = dehydration → confusion may worsen
  • Sweet taste; can mix with juice
  • If you can't take it orally, seek medical attention

Rifaximin:

  • Take twice daily with or without food
  • Prevents recurrence of confusion
  • May be expensive; ask about patient assistance programs

Prevention Strategies

  • Avoid constipation
  • Stay hydrated
  • Avoid sedatives, sleeping pills without physician approval
  • Avoid excessive salt intake (worsens fluid retention)
  • Maintain good nutrition
  • Avoid alcohol completely
  • Take medications as prescribed

Warning Signs Requiring Medical Attention

  • Worsening confusion
  • Increased sleepiness
  • Blood in stool or vomiting blood
  • Fever
  • Abdominal pain or increased swelling
  • Unable to take medications
  • Falls

Special Populations

Acute Liver Failure (Type A HE)

  • Different pathophysiology: Cerebral edema and elevated ICP are major concerns
  • Requires ICU-level care
  • ICP monitoring may be needed
  • Consider mannitol or hypertonic saline for elevated ICP
  • Liver transplant evaluation urgently
  • Lactulose is still used but managing ICP is critical

Post-TIPS

  • HE is a known complication of TIPS
  • Occurs in 30-50% of patients
  • May require TIPS reduction or embolization
  • Manage with lactulose and rifaximin

Minimal Hepatic Encephalopathy

  • Subclinical cognitive impairment
  • May affect driving, work performance
  • Treat with lactulose; rifaximin if needed
  • Specialist follow-up

Elderly

  • Higher mortality
  • More likely to have medication precipitants
  • Falls are common
  • May need more support at home

Quality Metrics

Performance Indicators

MetricTargetRationale
Precipitant identified>0%Treatment depends on cause
Lactulose initiated100% with overt HEFirst-line therapy
Diagnostic paracentesis for HE + ascites100%Rule out SBP
Alternative diagnoses excluded100%HE is diagnosis of exclusion
Hepatology referral100% for new HESpecialty care
Transplant evaluation for recurrent HE>0%May be only definitive treatment

Documentation Requirements

  • Mental status using standard grading
  • Precipitant(s) identified or "unknown"
  • Lactulose dosing and patient response
  • Paracentesis results if performed
  • Ammonia level (if obtained)
  • Alternative diagnoses considered and excluded
  • Discharge plan including medication instructions

Key Clinical Pearls

Diagnostic Pearls

  • HE is a clinical diagnosis: Ammonia level doesn't define or grade severity
  • Always look for the precipitant: Treatment won't work without addressing it
  • Paracentesis is mandatory: If ascites + AMS, rule out SBP
  • Asterixis is not unique to HE: Also seen in uremia, hypoxia, sedatives
  • Normal ammonia doesn't exclude HE: Clinical assessment is paramount
  • Consider other diagnoses: Especially in cirrhosis (SDH from falls, intoxication)

Treatment Pearls

  • Lactulose goal is 2-3 soft stools: Titrate accordingly
  • Rectal lactulose works: If patient can't take PO
  • Don't protein restrict: Actually harmful; maintain nutrition
  • Rifaximin reduces recurrence: Consider adding for recurrent HE
  • Treat the precipitant: Antibiotics for SBP, GI bleed management, etc.
  • Avoid sedatives: Benzodiazepines worsen HE

Disposition Pearls

  • Admit all overt HE (Grade II+): Need hospital management
  • Transplant evaluation for recurrent: May be only cure
  • Education is essential: Medication compliance prevents recurrence
  • Family involvement: Patients may not recognize early symptoms

References
  1. Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by AASLD and EASL. Hepatology. 2014;60(2):715-735.
  2. Amodio P, et al. The nutritional management of hepatic encephalopathy. Hepatology. 2014;60(2):715-735.
  3. Montagnese S, et al. Sleep disturbance and hepatic encephalopathy. Metab Brain Dis. 2014;29(3):529-539.
  4. Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
  5. Cordoba J, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy. J Hepatol. 2014;60(2):275-281.
  6. Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol. 2011;7(4):222-233.
  7. Shawcross DL, et al. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis. 2005;20(3):169-179.
  8. UpToDate. Hepatic encephalopathy in adults: Clinical manifestations and diagnosis. 2024.

At a Glance

EvidenceStandard
Last UpdatedRecently

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines